Compound class:
Synthetic organic
Comment: JSF-3285 is an indazole antibacterial compound discovered using a structure-based approach to optimize DG167 (PubChem CID 70689295), a known inhibitor of Mycobacterium tuberculosis 3-oxoacyl-[acyl-carrier-protein] synthase 1 (also known as β-ketoacyl-ACP synthase, KasA) [2]. JSF-3285 is being investigated as a preclinical candidate for the treatment of tuberculosis (TB). The structure is claimed in patent WO2019046467A1 filed by Rutgers University [1].
|
|
References |
1. Freundlich JS, Alland D, Neiditch,MB, Kumar P, Capodagli G, Awasthi D, Ekins S. (2019)
Therapeutic indazoles. Patent number: WO2019046467A1. Assignee: Rutgers. Priority date: 29/08/2017. Publication date: 07/03/2019. |
2. Inoyama D, Awasthi D, Capodagli GC, Tsotetsi K, Sukheja P, Zimmerman M, Li SG, Jadhav R, Russo R, Wang X et al.. (2020)
A Preclinical Candidate Targeting Mycobacterium tuberculosis KasA. Cell Chem Biol, 27 (5): 560-570.e10. [PMID:32197094] |